» Articles » PMID: 35893893

Dyslipidaemia Is Associated with Severe Disease Activity and Poor Prognosis in Ulcerative Colitis: A Retrospective Cohort Study in China

Overview
Journal Nutrients
Date 2022 Jul 27
PMID 35893893
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clinical data on the correlation of dyslipidaemia with the long-term outcomes of ulcerative colitis (UC) are limited. This study aimed to evaluate the impact of lipid levels on disease activity and prognosis in UC. Methods: The retrospective data of UC patients who had detailed lipid profiles were collected from January 2003 to September 2020. All patients were followed-up to 30 September 2021. The long-term outcomes were UC-related surgery and tumorigenesis. Results: In total, 497 patients were included in the analysis. Compared to patients with normal lipid levels, those with dyslipidaemia commonly presented with more serious disease activity. Low high-density lipoprotein cholesterol (p < 0.05) levels were associated with higher risks of severe disease activity in UC. Regarding the long-term outcomes, patients with persistent dyslipidaemia were at higher risks of UC-related surgery (HR: 3.27, 95% CI: 1.86−5.75, p < 0.001) and tumorigenesis (HR: 7.92, 95% CI: 3.97−15.78, p < 0.001) and had shorter surgery- and tumour-free survival (p < 0.001) than patients with transient dyslipidaemia and normal lipid levels. Low levels of high-density lipoprotein cholesterol (p < 0.001) and apolipoprotein A1 (p < 0.05) were associated with higher risks of surgery and tumorigenesis. Conclusion: Persistent dyslipidaemia was associated with a higher risk of serious disease activity and worse long-term outcomes among patients with UC. Lipid patterns should be assessed to improve the management of high-risk patients with UC in the early phase.

Citing Articles

Blood Lipid Levels and Their Value as Markers of Disease Activity in Severe Ulcerative Colitis.

Zhu L, Tian L, Li S, Huo L Int J Gen Med. 2025; 18:671-680.

PMID: 39959458 PMC: 11829746. DOI: 10.2147/IJGM.S481323.


To explore the causal association between the serum lipid profile and inflammatory bowel disease using bidirectional Mendelian randomisation analysis.

Pang X, Yang H, Li M, Suarez-Farinas M, Tian S eGastroenterology. 2025; 2(2):e100034.

PMID: 39944468 PMC: 11770443. DOI: 10.1136/egastro-2023-100034.


Myopenia and body fat distribution in hospitalized ulcerative colitis patients: correlations with clinical characteristics and response to vedolizumab.

Wei W, Yan P, Zhang Y, Wang Q, Kang J, Liu P Front Nutr. 2025; 11:1411695.

PMID: 39758314 PMC: 11695233. DOI: 10.3389/fnut.2024.1411695.


Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease.

Njeim R, Pannala S, Zaidan N, Habib T, Rajamanuri M, Moussa E J Clin Med. 2024; 13(22).

PMID: 39598052 PMC: 11594857. DOI: 10.3390/jcm13226908.


Predictive Value of MHR and NLR for Ulcerative Colitis Disease Activity.

Liu T, Qin Z, Yang Z, Feng X Int J Gen Med. 2024; 17:685-692.

PMID: 38435113 PMC: 10908246. DOI: 10.2147/IJGM.S446723.


References
1.
Becker S, McClave S . Lipid profiles in Crohn's disease patients with and without ileal resection. Am J Gastroenterol. 1996; 91(11):2452. View

2.
Primatesta P, Poulter N . Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf). 2006; 64(3):292-8. DOI: 10.1111/j.1365-2265.2006.02459.x. View

3.
Catapano A, Pirillo A, Bonacina F, Norata G . HDL in innate and adaptive immunity. Cardiovasc Res. 2014; 103(3):372-83. DOI: 10.1093/cvr/cvu150. View

4.
Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

5.
Beaugerie L, Itzkowitz S . Cancers complicating inflammatory bowel disease. N Engl J Med. 2015; 372(15):1441-52. DOI: 10.1056/NEJMra1403718. View